ATE165738T1 - Behandlung von gastro-intestinalen krankheiten - Google Patents

Behandlung von gastro-intestinalen krankheiten

Info

Publication number
ATE165738T1
ATE165738T1 AT89909128T AT89909128T ATE165738T1 AT E165738 T1 ATE165738 T1 AT E165738T1 AT 89909128 T AT89909128 T AT 89909128T AT 89909128 T AT89909128 T AT 89909128T AT E165738 T1 ATE165738 T1 AT E165738T1
Authority
AT
Austria
Prior art keywords
microflora
gastro
treatment
host
intestinal diseases
Prior art date
Application number
AT89909128T
Other languages
English (en)
Inventor
Services Pty Limited Gastro
Original Assignee
Gastro Services Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gastro Services Pty Ltd filed Critical Gastro Services Pty Ltd
Application granted granted Critical
Publication of ATE165738T1 publication Critical patent/ATE165738T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT89909128T 1988-08-02 1989-08-02 Behandlung von gastro-intestinalen krankheiten ATE165738T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPI961388 1988-08-02
AUPJ383789 1989-04-21

Publications (1)

Publication Number Publication Date
ATE165738T1 true ATE165738T1 (de) 1998-05-15

Family

ID=25643518

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89909128T ATE165738T1 (de) 1988-08-02 1989-08-02 Behandlung von gastro-intestinalen krankheiten

Country Status (5)

Country Link
EP (1) EP0433299B1 (de)
AT (1) ATE165738T1 (de)
CA (1) CA1333564C (de)
DE (1) DE68928665T2 (de)
WO (1) WO1990001335A1 (de)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE496989T1 (de) 1997-02-11 2011-02-15 Entpr Ie Trd As Bioresearch Ie Probiotische stämme des lactobacillus salivarius und daraus hergestellte antimikrobielle mittel
IT1299070B1 (it) * 1998-04-10 2000-02-07 Proge Farm Srl Ceppi di lattobacilli capaci di inibire e/o avere azione microbicida nei confronti di microorganismi patogeni e metodo di induzione e
ID29150A (id) 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
SE523136C2 (sv) * 1999-12-21 2004-03-30 Gottfriesmottagningen Ab Användning av stafylokockbakterier i samband med behandling av irritable bowelsyndrome
AUPQ899700A0 (en) * 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
GB0127916D0 (en) * 2001-11-21 2002-01-16 Rowett Res Inst Method
AUPS088702A0 (en) 2002-03-04 2002-03-28 Borody, Thomas Julius Electrolyte purgative
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US7785635B1 (en) 2003-12-19 2010-08-31 The Procter & Gamble Company Methods of use of probiotic lactobacilli for companion animals
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US8894991B2 (en) 2003-12-19 2014-11-25 The Iams Company Canine probiotic Lactobacilli
US20050152884A1 (en) 2003-12-19 2005-07-14 The Procter & Gamble Company Canine probiotic Bifidobacteria globosum
CA2607949C (en) 2005-05-31 2012-09-25 Thomas William-Maxwell Boileau Feline probiotic bifidobacteria
JP4938005B2 (ja) 2005-05-31 2012-05-23 ザ・アイムス・カンパニー ネコ科動物プロバイオティックであるラクトバシラス
PL1920781T3 (pl) 2006-11-10 2015-06-30 Glycotope Gmbh Kompozycje zawierające core-1-dodatnie mikroorganizmy i ich zastosowanie w leczeniu lub profilaktyce nowotworów
AU2008211600B8 (en) 2007-02-01 2014-02-13 Mars, Incorporated Method for decreasing inflammation and stress in a mammal using glucose antimetabolites, avocado or avocado extracts
CA2740434C (en) 2007-10-26 2017-11-07 Brenda E. Moore Probiotic compositions and methods for inducing and supporting weight loss
CN102940652B (zh) * 2008-05-28 2015-03-25 青岛东海药业有限公司 两形真杆菌制剂及其应用
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
GB0916335D0 (en) * 2009-09-17 2009-10-28 Martin W J Medicaments
ES2730828T3 (es) 2010-02-01 2019-11-12 Rebiotix Inc Bacterioterapia para la colitis por Clostridium difficile
RU2013109251A (ru) 2010-08-04 2014-09-10 Томас Джулиус БОРОДИ Композиции для трансплантации фекальной флоры и способы их получения и применения и устройства для их доставки
JP6121334B2 (ja) 2010-12-13 2017-04-26 サリックス ファーマシューティカルズ，インコーポレイテッド 胃および結腸製剤ならびにそれらを作製するための方法および使用するための方法
SG193348A1 (en) 2011-03-09 2013-10-30 Univ Minnesota Compositions and methods for transplantation of colon microbiota
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
CN108771687A (zh) 2012-02-29 2018-11-09 伊西康内外科公司 微生物区系的组合物及与其相关的方法
US9719144B2 (en) 2012-05-25 2017-08-01 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
RU2015106688A (ru) 2012-07-27 2016-09-20 Редхилл Байофарма Лтд. Препараты и способы получения препаратов для применения при опорожнении толстой кишки
SG11201503966PA (en) 2012-11-23 2015-06-29 Seres Health Inc Synergistic bacterial compositions and methods of production and use thereof
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
US11179427B2 (en) 2013-01-21 2021-11-23 Eth Zurich Baby food composition comprising viable propionic acid-producing bacteria
WO2014121304A1 (en) 2013-02-04 2014-08-07 Seres Health, Inc. Compositions and methods
EP2956006A4 (de) 2013-02-04 2017-02-22 Seres Therapeutics, Inc. Verfahren zum bevölkern des gastrointestinalen traktes
CA2906921A1 (en) 2013-03-15 2014-09-18 Seres Therapeutics, Inc. Network-based microbial compositions and methods
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
US9782445B2 (en) 2013-06-05 2017-10-10 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US10383901B2 (en) 2013-06-05 2019-08-20 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9511099B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9511100B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9694039B2 (en) 2013-06-05 2017-07-04 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
EP3375447A1 (de) 2013-06-05 2018-09-19 Rebiotix, Inc. Mikrobiotawiederherstellungstherapie (mrt), zusammensetzungen und verfahren zur herstellung
AU2014352643A1 (en) 2013-11-25 2016-06-30 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
WO2015095241A2 (en) 2013-12-16 2015-06-25 Seres Health, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
WO2016019505A1 (en) * 2014-08-05 2016-02-11 Bgi Shenzhen Co., Limited Use of eubacterium in the prevention and treatment for colorectal cancer related diseases
CN106687130B (zh) * 2014-08-05 2020-01-21 深圳华大基因科技有限公司 真杆菌属在预防和治疗结直肠癌相关疾病中的用途
CN104546951B (zh) * 2014-09-30 2019-03-01 深圳华大基因科技有限公司 规则粪球菌在治疗或预防类风湿性关节炎或其相关疾病中的应用
GB2551642B (en) 2014-10-31 2020-09-23 Pendulum Therapeutics Inc Methods and compositions relating to microbial treatment and diagnosis of disorders
MA41020A (fr) 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
GB201421735D0 (en) * 2014-12-07 2015-01-21 Craig Nicola M Humanized gut microbiota
JP6271093B1 (ja) 2014-12-23 2018-01-31 フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ 免疫調節
ES2668934T3 (es) 2014-12-23 2018-05-23 4D Pharma Research Limited Polipéptido pirin y modulación inmune
CN114159476A (zh) 2015-05-14 2022-03-11 克雷斯顿沃控股公司 用于粪便菌群移植的组合物以及用于制备和使用它们的方法和用于递送它们的装置
WO2016183535A1 (en) 2015-05-14 2016-11-17 University Of Puerto Rico Methods for restoring microbiota of newborns
EP3297644B1 (de) 2015-05-22 2022-01-19 Arizona Board of Regents on behalf of Arizona State University Verfahren zur behandlung von störungen des autismusspektrums und damit verbundener symptome
US10828340B2 (en) 2015-06-09 2020-11-10 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10799539B2 (en) 2015-06-09 2020-10-13 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
CA2986915C (en) 2015-06-09 2023-09-19 Rebiotix, Inc. Microbiota restoration therapy (mrt) compositions and methods of manufacture
US10905726B2 (en) 2015-06-09 2021-02-02 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
PE20180243A1 (es) 2015-06-15 2018-01-31 4D Pharma Res Ltd Composiciones que comprenden cepas bacterianas
PE20180267A1 (es) 2015-06-15 2018-02-06 4D Pharma Res Ltd Composiciones que comprenden cepas bacterianas
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
NZ777234A (en) 2015-06-15 2022-02-25 4D Pharma Res Ltd Compositions comprising bacterial strains
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
ES2662617T3 (es) 2015-11-20 2018-04-09 4D Pharma Research Limited Composiciones que comprenden cepas bacterianas
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
US11564667B2 (en) 2015-12-28 2023-01-31 New York University Device and method of restoring microbiota of newborns
CN114712405A (zh) 2016-03-04 2022-07-08 4D制药有限公司 包含细菌菌株的组合物
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
US20170360848A1 (en) 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US10849936B2 (en) 2016-07-01 2020-12-01 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
TW201821093A (zh) 2016-07-13 2018-06-16 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
US20180036352A1 (en) 2016-08-03 2018-02-08 Crestovo Holdings Llc Methods for treating ulcerative colitis
US11213549B2 (en) 2016-10-11 2022-01-04 Finch Therapeutics Holdings Llc Compositions and method for treating primary sclerosing cholangitis and related disorders
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
WO2018071537A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
JP2020513018A (ja) 2017-04-05 2020-04-30 クレストヴォ・ホールディングス・エルエルシー パーキンソン病（ｐｄ）および関連する障害を治療するための組成物および方法
US11040073B2 (en) 2017-04-05 2021-06-22 Finch Therapeutics Holdings Llc Compositions and methods for treating diverticulitis and related disorders
RS61872B1 (sr) 2017-05-22 2021-06-30 4D Pharma Res Ltd Kompozicije koje sadrže bakterijske sojeve
JP6978514B2 (ja) 2017-05-24 2021-12-08 フォーディー ファーマ リサーチ リミテッド4D Pharma Research Limited 細菌株を含む組成物
US11890306B2 (en) 2017-05-26 2024-02-06 Finch Therapeutics Holdings Llc Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same
AU2018285445B2 (en) 2017-06-14 2020-03-26 Cj Bioscience, Inc. Compositions comprising bacterial strains
EP3600364B1 (de) 2017-06-14 2020-08-05 4D Pharma Research Limited Zusammensetzungen mit einem bakterienstamm der gattung megasphaera und verwendungen davon
HUE052319T2 (hu) 2017-06-14 2021-04-28 4D Pharma Res Ltd Baktériumtörzseket tartalmazó készítmények
RU2659417C1 (ru) * 2017-06-22 2018-07-02 Федеральное государственное бюджетное научное учреждение "Иркутский научный центр хирургии и травматологии" Устройство для подготовки донорского фекального материала к трансплантации
JP2020530494A (ja) 2017-08-07 2020-10-22 フィンチ セラピューティクス、インコーポレイテッド． 健康な腸バリアを維持及び回復するための組成物及び方法
CA3072206A1 (en) 2017-08-14 2019-02-21 Seres Therapeutics, Inc. Compositions and methods for treating cholestatic disease
JP2020532515A (ja) 2017-08-30 2020-11-12 ペンデュラム セラピューティクス， インコーポレイテッド マイクロバイオーム関連障害の処置のための方法および組成物
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
KR20200021257A (ko) * 2018-08-20 2020-02-28 아주대학교산학협력단 유박테리움 렉탈레를 포함하는 베체트병 또는 헤르페스 바이러스 감염증의 예방 또는 치료용 조성물
CN113164527A (zh) 2018-09-27 2021-07-23 芬奇治疗控股有限责任公司 用于治疗癫痫和相关障碍的组合物和方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1275M (fr) * 1961-05-06 1962-05-02 Rene Roger Médicament a base de colibacilles vivants.
NL294835A (de) * 1962-07-19 1900-01-01
FR2828M (fr) * 1963-03-01 1964-11-02 Lucien Nouvel Médicament renfermant des colibacilles antibiorésistants.
FR5528M (de) * 1965-10-01 1967-11-13
GB1271674A (en) * 1968-07-09 1972-04-26 Nisshin Flour Milling Co Process and preparation for treating diarrhoea in pigs
SE371209B (de) * 1969-10-13 1974-11-11 Cernelle Ab
DE2134179A1 (de) * 1971-07-09 1973-01-25 Rolf Dr Schuler Bifidobakterien enthaltendes praeparat und verfahren zur herstellung desselben
FR2244464A1 (en) * 1973-06-26 1975-04-18 Serozym Laboratoires Yeast, lacto- and colibacillus based compsns - used to modify intestinal flora, treat colitis and digestive disorders, etc.
US4335107A (en) * 1978-06-05 1982-06-15 Snoeyenbos Glenn H Mixture to protect poultry from salmonella
CH637297A5 (fr) * 1978-12-05 1983-07-29 Nestle Sa Microbille comprenant un microorganisme et son procede de fabrication.
FI840816A0 (fi) * 1984-03-01 1984-03-01 Farmos Oy Bakteriepreparat

Also Published As

Publication number Publication date
EP0433299A1 (de) 1991-06-26
CA1333564C (en) 1994-12-20
EP0433299B1 (de) 1998-05-06
EP0433299A4 (en) 1992-04-08
DE68928665D1 (de) 1998-06-10
WO1990001335A1 (en) 1990-02-22
DE68928665T2 (de) 1998-11-12

Similar Documents

Publication Publication Date Title
ATE165738T1 (de) Behandlung von gastro-intestinalen krankheiten
Kozarek et al. Endoscopic approach to pancreas divisum
FI833605A (fi) Ny oral mopidamolprodukt
DE59310327D1 (de) Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura
ATE153534T1 (de) Verfahren und zusammensetzung zur behandlung von erkrankungen des zns hervorgerufen durch abnormales beta-amyloid-protein
PT782841E (pt) Dispositivo de introducao para uma protese endoluminal com protese endoluminal
CA2092905A1 (en) Treatment of autoimmune diseases by oral administration of autoantigens
DE3873800D1 (de) Zusammensetzungen zur behandlung von hypercholesterinaemie.
ES2161780T3 (es) Polimeros que ligan fosfato para administracion oral.
ATE281840T1 (de) Behandlung von diarrhoe
DE69526937D1 (de) Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen
UY25263A1 (es) 6-derivados sustitutivos del ácido micofenólico.-
DE19975006I2 (de) Pharmazeutische Zusammensetzungen zur Behandlung gastrointestinaler St¦rungen.
AU5051693A (en) Method and composition for treating inflammatory bowel disorders
WO1998032428A3 (en) Compositions comprising choline and use of choline to treat endotoxic shock
ATE198049T1 (de) Behandlung von magen- und darmgeschwüren mit morphogenen
EP0687687A3 (de) Pharmazeutische Zusammensetzung zur Vorbeugung und Behandlung von Blutgerinnungsstörungen
IL124730A0 (en) Compositions comprising bismuth and one or more antimicrobials for the prevention and treatment of gastrointestinal disorders
NO984198L (no) FremgangsmÕte for behandling av aggresjon
FR2719480B1 (fr) Compositions pharmaceutiques destinées à prévenir et/ou traiter l'expression du comportement de couvaison chez les oiseaux et plus particulièrement chez la dinde et leurs procédés de préparation.
DK32893A (da) Geminale cycloalkyldiphosphonsyrer og farmaceutisk acceptable salte heraf samt farmaceutisk sammensaetning omfattende samme
ATE85750T1 (de) Vorrichtung zur behandlung von verstauchungen, insbesondere der sprunggelenke sowie zur vermeidung von dabei auftretenden bestimmten komplikationen.
MX9804579A (es) Composiciones que contienen bismuto para la prevencion y tratamiento de trastornos gastrointestinales.
RU93035807A (ru) Способ лечения юношеского эпифизиолиса
DE68901234D1 (de) Arzneimittelzusammensetzung zur behandlung des lungenverstopfens.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties